CLBS-03

N/A

Report date: 2025/01/02 16:12:09

Base Information

Drug NameCLBS-03
Drug Alias NameCLBS-03
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TregsCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsDiabetes Mellitus, Type 1Lupus Erythematosus, SystemicLupus Erythematosus, Discoid +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCaladrius Biosciences IncBecton, Dickinson BvUc San Francisco
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of California San FranciscoLisata Therapeutics IncNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 1Lupus Erythematosus, SystemicLupus Erythematosus, Discoid +[4] 

Other Information

ATC CodeN/A
Related LinksN/A